Core Insights - GSK has transformed its respiratory business over the past three years, evolving from a focus on inhaled medications to a comprehensive respiratory health ecosystem that includes prevention, treatment, and management solutions [1][2][4] - The rapid approval of innovative drugs in China has significantly increased the accessibility of these treatments for patients, with the number of approved innovative drugs expected to be more than five times that of 2018 by 2024 [1][6] - GSK's strategic shift towards biologics has led to the successful launch of new products, including the biologic drug Nucala, which has expanded its indications rapidly in the Chinese market [5][6] Product Pipeline Innovation - GSK's initial product line primarily consisted of inhaled medications, which effectively addressed the needs of over 40 million asthma and nearly 100 million COPD patients in China [3][4] - The company has recognized the limitations of inhaled medications, prompting a strategic pivot towards biologics to provide more effective solutions for difficult-to-treat patients [4][6] - GSK's product pipeline now includes a complete range of respiratory treatments, from vaccines to inhaled and biologic therapies, ensuring comprehensive patient protection [6] Business Model Innovation - GSK's transformation is driven by a commitment to patient-centered care, moving from a focus on individual products to offering comprehensive disease management solutions [2][8] - The establishment of standardized diagnostic centers for eosinophils (EOS) exemplifies GSK's innovative approach to improving patient outcomes through better disease management [8][9] - GSK is leveraging digital tools and partnerships with internet companies to enhance drug accessibility and optimize healthcare resource allocation, particularly in remote areas [9] Team Empowerment - GSK has achieved significant productivity improvements, with team efficiency increasing by 2 to 3 times despite maintaining a similar team size [10] - The company emphasizes the importance of developing key capabilities among its medical representatives, including policy interpretation, academic expertise, channel development, and digital application skills [10] - GSK's training programs aim to cultivate a skilled workforce that understands both medical and market dynamics, fostering continuous innovation [10] Future Outlook - GSK's future strategy focuses on accelerating the launch of biologics, expanding treatment indications, and responding to national healthcare policies [11] - The company's vision is to enhance patients' quality of life through innovative treatments and comprehensive disease management services, ensuring that patients can enjoy a better quality of life [11]